Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis Defense Against Sanofi: Strong Pipeline Or Irrational “Exubera-nce”?

Executive Summary

Aventis is using the prospects of Genasense as its first line of defense against Sanofi's hostile takeover bid

You may also be interested in...



Ketek Launch Is First For Sanofi-Aventis; Merger Will Test Focus

Ketek will be the first product launch for the newly formed Sanofi-Aventis

Ketek Launch Is First For Sanofi-Aventis; Merger Will Test Focus

Ketek will be the first product launch for the newly formed Sanofi-Aventis

P&G Pharma Keeps Low Profile In Reorganization; Squeezes In With Charmin

Procter & Gamble has ambitious plans for growing its health care business - but the role for its prescription drugs business is likely to remain decidedly low-key

Related Content

UsernamePublicRestriction

Register

PS043285

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel